Trial Information

Summary: A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.

Status: Recruiting

Protocol Number: BA20341

Sponsor: Hoffmann-La Roche

Company Division: Pharmaceutical

Official Scientific Title: A randomized, open label study evaluating the effect on renal function of intravenous Bonviva given by injection or infusion, compared with oral alendronate, in postmenopausal women with osteoporosis at high risk for renal disease.

Brief Summary: This 3 arm study will evaluate renal safety after administration of an intravenous injection or infusion of Bonviva, compared to oral alendronate, in patients with postmenopausal osteoporosis,at increased risk of renal disease. Patients will be randomized to receive Bonviva 3mg i.v. by a) injection or b)infusion once every 3 months, or alendronate 70mg p.o. weekly. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals. Target sample size is 801.

Study Phase: IV

Study Design / Study Details:

  • Purpose: Treatment
  • Allocation: Randomized
  • Masking: Open Label
  • Control: Active
  • Assignment: Parallel
  • Endpoints: Safety

Study Type:

Interventional

Condition: Post-Menopausal Osteoporosis

Intervention Type: Drug

Intervention Name: ibandronate [Bonviva/Boniva]

Primary Outcome: 1. Change from baseline in actual GFR Time frame: 9 months

Key Secondary Outcomes: 1. Relative and absolute change in mean actual GFR, serum creatinine and urine albumin-creatinine ratio Time frame: 9 months

Inclusion Criteria:

  • female patients, >=60 years of age;
  • >=5 years postmenopausal;
  • confirmed osteoporosis, at increased risk for renal disease.

Exclusion Criteria:

  • inability to stand or sit upright for 30 minutes;
  • hypersensitivity to bisphosphonates;
  • malignant disease (other than successfully resected basal cell cancer) within previous 10 years, or breast cancer diagnosed within previous 20 years;
  • previous administration of an i.v. bisphosphonate;
  • oral bisphosphonate treatment other than study medication within 30 days prior to the baseline dosing visit and during the study;
  • history of major upper gastrointestinal disease.

Gender: Females

Age Limits: Min: 60 Years

Accepts Healthy Volunteers: No

Anticipated Start Date: July, 2007

Trial Registration Date: 07/19/2007

Date Last Updated: 08/18/2008

Link To Trial Results

Contact:

Research Site:
Located In:
Birmingham, AL 35209
Telephone: 973-235-5000 or 800-526-6367

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: September 2, 2008 at 1:55:28 PM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA